Rios-Guzman, Estefany http://orcid.org/0000-0002-1399-7546
Simons, Lacy M. http://orcid.org/0000-0003-4041-6775
Dean, Taylor J.
Agnes, Francesca
Pawlowski, Anna http://orcid.org/0000-0002-9047-6437
Alisoltanidehkordi, Arghavan
Nam, Hannah H.
Ison, Michael G.
Ozer, Egon A. http://orcid.org/0000-0002-7131-3691
Lorenzo-Redondo, Ramon http://orcid.org/0000-0002-5462-9483
Hultquist, Judd F. http://orcid.org/0000-0001-6424-4280
Article History
Received: 12 December 2023
Accepted: 11 April 2024
First Online: 20 April 2024
Competing interests
: M.G.I. declares that research support from GSK was paid to his previous institution, Northwestern University; he received consulting fees from Adagio Therapeutics, ADMA Biologics, Adamis Pharmaceuticals, AlloVir, Atea, Cidara Therapeutics, Genentech/Roche, Janssen, Shionogi, Takeda, Talaris, and Eurofins Viracor; and payment for participating in data safety monitoring boards or advisory boards from Adamis Pharmaceuticals, AlloVir, National Institutes of Health, CSL Behring, Janssen, Merck, Seqirus, Takeda, and Talaris; all of these ended in December 2022; M.G.I. also receives author royalties from UpToDate, which is ongoing. J.F.H. received research support, paid to Northwestern University, from Gilead Sciences and is a paid consultant for Merck. E.R.G has previously been a paid consultant for Merck. All other authors declare no conflicts of interest.